Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7876
-0.0074 (-0.93%)
At close: Sep 12, 2025, 4:00 PM EDT
0.7899
+0.0023 (0.29%)
After-hours: Sep 12, 2025, 7:55 PM EDT
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Than Powell |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L2034 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls |
| Jen Dumas | Vice President of Human Resources |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 3, 2025 | 8-K | Current Report |
| Aug 27, 2025 | SCHEDULE 13G | Filing |
| Aug 15, 2025 | SCHEDULE 13G | Filing |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 424B4 | Prospectus |
| Aug 8, 2025 | EFFECT | Notice of Effectiveness |
| Aug 8, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 4, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |